GT BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2020-12-31 was 0.00 shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2020-09-30 was 0.00 shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2020-06-30 was 0.00 shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2020-03-31 was 0.00 shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2020 was 0.00 shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2019 was 0.00 shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2018 was 0.00 shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2017 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2020-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-04-16 | 0.00 shares 10-K · filed 2021-04-16 |
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q/A 6 month · filed 2020-11-13 | |
| 2020-06-30 | 0.00 shares derived: 10-Q/A 6 month − 10-Q 3 month · filed 2020-08-18 | |
| 2020-03-31 | 0.00 shares 10-Q · filed 2020-05-15 | |
| 2019-12-31 | 0.00 shares 10-K · filed 2021-04-16 | |
| 2018-12-31 | 0.00 shares 10-K · filed 2020-03-27 | |
| 2017-12-31 | 0.00 shares 10-K · filed 2019-03-29 | |
| 2016-12-31 | 0.00 shares 10-K · filed 2018-03-01 | |
| 2012-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2014-11-18 | 0.00 shares 10-K · filed 2014-11-18 |
| 2011-12-31 | 0.00 shares 10-K · filed 2014-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |